ViiV Healthcare receives EU Marketing Authorisation for Dovato (dolutegravir/lamivudine), a new once-daily, single-pill, two-drug regimen for the treatment of HIV-1 infection - Global Banking And Finance Review

ViiV Healthcare receives EU Marketing Authorisation for Dovato (dolutegravir/lamivudine), a new once-daily, single-pill, two-drug regimen for the treatment of HIV-1 infection  Global Banking And Finance Review

ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announc.



Comments

Popular posts from this blog

The Best Flea Treatments for Cats and Dogs

Everything You Need to Know About Mite and Flea Bites

Is Citronella Safe for Dogs? A Veterinarian Provides Guidance